IN8BIO, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
INAB$0.90-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(10,644) | $(17,191) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 511 | 473 |
| Non-cash stock-based compensation | 1,786 | 2,411 |
| Amortization of finance lease right-of-use assets | 526 | 397 |
| Amortization of operating lease right-of-use assets | 416 | 393 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 943 | 878 |
| Other non-current assets | — | (65) |
| Accounts payable | (10) | 518 |
| Accrued expenses and other current liabilities | (412) | (1,422) |
| Short-term operating lease liabilities | 225 | 69 |
| Long-term operating lease liabilities | (390) | (471) |
| Net cash used in operating activities | (7,049) | (14,010) |
| Investing activities | ||
| Purchases of property and equipment | — | (71) |
| Construction in progress | — | (83) |
| Net cash used in investing activities | — | (154) |
| Financing activities | ||
| Payment of issuance costs from December 2023 issuance of common stock | — | (89) |
| Proceeds from the issuance of common stock, net of issuance costs | 7,352 | 3,528 |
| Proceeds from the exercise of Series A & B warrants, net of issuance costs | 1,884 | 25 |
| Proceeds from the exercise of Series C warrants, net of issuance costs | 383 | — |
| Principal payments on finance leases | (459) | (362) |
| Net cash provided by financing activities | 9,160 | 3,102 |
| Net increase (decrease) in cash and restricted cash | 2,111 | (11,062) |
| Cash and restricted cash at beginning of period | 11,386 | 21,538 |
| Cash and restricted cash at end of period | $13,497 | $10,476 |
| Cash, end of period | $13,226 | $10,217 |
| Restricted cash, end of period | 271 | 259 |
| Cash and restricted cash, end of period | $13,497 | $10,476 |
| Supplemental disclosure of non-cash financing and investing activities: | ||
| Initial measurement of operating lease right-of-use assets and liabilities | $— | $714 |
| Initial measurement of finance lease right-of-use assets and liabilities | $— | $564 |
| Lease modification of operating lease right-of-use assets and liabilities | $(1,287) | $492 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.